Durvalumab Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 120 mg/4 mL, 500 mg/10 mL
Reference Brands: Imfinzi® (US & EU)
Category: Oncology Cancer Care
Durvalumab (Imfinzi®) is a PD-L1 checkpoint inhibitor used for urothelial carcinoma and NSCLC treatment. Available as sterile intravenous infusion vials (120 mg/4 mL, 500 mg/10 mL), it complies with EU-GMP and USFDA standards. Offered for B2B supply, hospital tenders, and licensing in regulated markets. Durvalumab is available in Injection and strengths such as 120 mg/4 mL, 500 mg/10 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Durvalumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Durvalumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Durvalumab (Imfinzi®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma and non-small cell lung cancer. Provided as sterile intravenous infusion vials (120 mg/4 mL and 500 mg/10 mL), Durvalumab is manufactured under EU-GMP and USFDA standards. Available for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody enhances anti-tumor immunity by blocking PD-L1, making it a critical drug in immuno-oncology portfolios across the US and European markets.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Durvalumab is used to treat certain types of cancer, including unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy and extensive-stage small cell lung cancer (ES-SCLC) in combination with chemotherapy. It is also indicated for advanced or metastatic urothelial carcinoma. Durvalumab works by helping the immune system detect and attack cancer cells more effectively.
Durvalumab is a fully human monoclonal antibody made using recombinant DNA technology. It specifically targets and blocks the programmed death-ligand 1 (PD-L1) protein on cancer cells, which allows T cells to recognize and destroy these cells. The active ingredient is Durvalumab, and inactive components include histidine, sucrose, polysorbate 80, and water for injection.
The trade name of Durvalumab is Imfinzi.
Durvalumab is developed and manufactured by AstraZeneca Pharmaceuticals LP, a leading global biopharmaceutical company headquartered in the United Kingdom.
The generic name of the product is Durvalumab.
The brand name of the product is Imfinzi.
Durvalumab (Imfinzi) is manufactured by AstraZeneca at facilities located in the United Kingdom and the United States, and it is also produced in other AstraZeneca manufacturing sites in Europe to meet global demand.
Related Products
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
